脂代謝與動(dòng)脈粥樣硬化(已修改)
2025-05-14 05:13 本頁面
【正文】 Cardiovascular disease is the leading cause of death among adults worldwide (1996) Coronary disease million Cancer Cerebrovascular disease Acute lower respiratory tract infections Tuberculosis COPD (chronic obstructive pulmonary disease) Diarrhea (including dysentery) Malaria AIDS Hepatitis B Coronary mortality: alarming worldwide forecasts Atherosclerosis: a multifactorial disease Main risk factors for coronary heart disease Global projections for the diabetes epidemic: 19952022 Atherosclerosis Arterial wall: structure and function Different stages of atherosclerotic plaque development Vascular endothelium modification in atherosclerosis Plaque formation 1 — Fatty streak Plaque formation 2 — Fibrous cap Plaque formation 3 — Lipid core From plaque to thrombosis, key event: plaque rupture Lipid core constitution Activated macrophages accumulate lipids Lipid core constitution LDL oxidation Parietal vascular inflammation The activated macrophage produces inflammatory cytokines Parietal vascular inflammation NFkB action in the inflammation process Diabetes and atherosclerosis Tobacco and atherosclerosis Dyslipidemia and atherosclerosis HTN, hemodynamic factor and atheroclerosis How to reduce plaque formation Intervention on risk factors How to reduce the risk of plaque rupture How to reduce the risk of thrombosis ~10% Weight loss = ~30% Visceral adipose tissue loss Characteristics of an unstable plaque Plaque vulnerability factors Intrinsic factors Modification of extrinsic vulnerability factors Plaque rupture The main releasing factors Classification of lipids and lipoproteins Characteristics of lipoproteins Triglyceriderich lipoproteins: size, structure and position Digestion and metabolism of dietary fat HDL metabolism and reverse cholesterol transport Cholesterol efflux and reverse cholesterol transport is modulated by two receptors Atherogenicity of small dense LDL Size and apolipoprotein position are the main factors determining atherogenicity of triglyceriderich particles Size and apolipoprotein position are the main factors determining atherogenicity of triglyceriderich particles Apo CIII modulates VLDL Apo CIII in apo B particles is atherogenic Relationship between apo CIII in apo B containing lipoproteins and atherogenicity PROCAM Study MIIncidence according to LDLcholesterol and triglycerides PROCAM Study CHD risk according to LDLC and TG increased TG confers raised CHD risk at all levels of LDLC HDL: an antiatherogenic lipoprotein HDL metabolism: 5 key genes HDL: apo AIrich particles Apo AI protects against atherosclerosis Apo AII protects against atherosclerosis The human apo AII transgenic mouse model Genes and environment in type 2 diabetes and atherosclerosis Pima Indians Thrifty genes Aboriginal Canadians OjiCree Obesity, type 2 diabetes, atherosclerosis The Metabolic Syndrome Visceral obesity is associated with a cluster of metabolic abnormalities The atherogenic triad PROCAM Study: MIIncidence according to LDLcholesterol and triglycerides 70% of men with CHD had a low HDL ≤44mg/dL Framingham Male Offspring 3554 Obesity, type 2 diabetes, lipid metabolism The key role of the transcr
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1